Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment
In the first segment of Nine for 2024, we examined the continued fragility of healthcare systems, global pharmaceutical market infrastructure, and the journey to greater resilience.
The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid
Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel
Novo Nordisk has reaped the first harvest from its wide-ranging alliance with life sciences investor Flagship Pioneering, buying rights to two programmes from the VC’s por
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.